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Engineering of Isogenic Cells Deficient for MR1 with a
CRISPR/Cas9 Lentiviral System: Tools To Study Microbial
Antigen Processing and Presentation to Human
MR1-Restricted T Cells
Bruno Laugel,*,1,2 Angharad Lloyd,*,2 Erin W. Meermeier,† Michael D. Crowther,*
Thomas R. Connor,‡ Garry Dolton,* John J. Miles,x Scott R. Burrows,x Marielle C. Gold,†
David M. Lewinsohn,‡ and Andrew K. Sewell*
The nonclassical HLA molecule MHC-related protein 1 (MR1) presents metabolites of the vitamin B synthesis pathways to
mucosal-associated invariant T (MAIT) cells and other MR1-restricted T cells. This new class of Ags represents a variation
on the classical paradigm of self/non-self discrimination because these T cells are activated through their TCR by small organic
compounds generated during microbial vitamin B2 synthesis. Beyond the fundamental significance, the invariant nature of MR1
across the human population is a tantalizing feature for the potential development of universal immune therapeutic and
diagnostic tools. However, many aspects of MR1 Ag presentation and MR1-restricted T cell biology remain unknown, and
the ubiquitous expression of MR1 across tissues and cell lines can be a confounding factor for experimental purposes. In this
study, we report the development of a novel CRISPR/Cas9 genome editing lentiviral system and its use to efficiently disrupt
MR1 expression in A459, THP-1, and K562 cell lines. We generated isogenic MR12/2 clonal derivatives of the A549 lung
carcinoma and THP-1 monocytic cell lines and used these to study T cell responses to intracellular pathogens. We confirmed
that MAIT cell clones were unable to respond to MR12/2 clones infected with bacteria whereas Ag presentation by classical
and other nonclassical HLAs was unaffected. This system represents a robust and efficient method to disrupt the expression of
MR1 and should facilitate investigations into the processing and presentation of MR1 Ags as well as into the biology of
MAIT cells. The Journal of Immunology, 2016, 197: 971–982.
M
ucosal-associated invariant T (MAIT) cells are the most
abundant nonconventional T cell subset, accounting for
up to 5% of all T cells in humans, and are thought to be
important for the control of a number of bacterial, fungal, and yeast
infections (1–5). These so-called innate-like T cells, which are
mostly found in the blood, the liver, and at mucosal surfaces,
express a semi-invariant TCR consisting of an a-chain using the
canonical TRAV1-2–TRAJ33/12/20 (Va7.2-Ja33/12/20) rear-
rangements (6). MAIT cells acquire effector functions during
thymic selection and readily respond to Ags derived from many
(but not all) bacteria such as Escherichia coli, Klebsiella pneu-
moniae, Mycobacterium tuberculosis, or Staphylococcus epider-
mis as well as several yeast species in the periphery without prior
priming (3, 7). MAIT cell activation is mediated by the interaction
between the TCR and microbe-derived Ags presented by the
nonclassical MHC-related protein 1 (MR1) and results in the
secretion of cytokines as well as in granzyme- and perforin-
dependent cytoxicity (2, 8). The nature of these Ags has been
recently discovered by Kjer-Nielsen et al. (9) who showed that
MR1 binds and presents small organic metabolite compounds
derived from the vitamin B synthesis pathways (10). A number of
intermediates of the folic acid (vitamin B9) and riboflavin (vitamin B2)
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pathways act as ligands for MR1 (10, 11). However, only com-
pounds derived from the riboflavin pathway, which is absent
in mammals but present in microbes, were found to activate
MAIT cells, therefore providing a molecular basis for the specific
recognition of microbially infected cells (9). Our recent study
showed that human MAIT cells isolated from a single individual
use distinct TCR repertoires to recognize cells infected with
different bacteria in an MR1-specific manner (12). Moreover,
Gherardin et al. (13) have recently characterized the crystal
structure and biophysical properties of TCRs from T cells with
discrete Ag specificity for folate- or riboflavin-derived compounds
presented by MR1. Remarkably, several of these MR1-restricted
T cell clonotypes did not express the canonical MAIT TRAV1-2
TCR a-chain (13), indicating that non-MAIT ab T cells are also
able to recognize MR1 Ags. This TCR usage heterogeneity may
provide a degree of specificity in MAIT- and MR1-restricted
T cell activation and hints that different pathogens could gener-
ate MR1-restricted Ags of varied structure and chemical compo-
sition. In addition to MR1-restricted activation, MAIT cells
respond to proinflammatory innate cytokines such as IL-12 and
IL-18 (1, 14), which can act as autonomous stimuli or combine
with TCR signals to potentiate MAIT cell activation (15). This
Ag-independent activation process may be relevant to the patho-
genesis of a number of inflammatory conditions in which the
number, distribution, phenotype, and functions of MAIT cells
were found to be altered (1, 16–18).
The biology of MR1-restricted T cells is a rapidly emerging field
in immunology. The invariant nature of MR1 across the human
population and its established role in the presentation of pathogen-
derived Ags are of outstanding interest for the potential devel-
opment of universal therapeutic and diagnostic tools in infectious
diseases. MR1 expression also appears to be ubiquitous among
different cells and tissues (19, 20), which may indicate that MR1-
driven Ag responses are relevant to the pathogenesis of a broad
number of immune-mediated diseases. However, the invariance
and ubiquity of MR1 also complicate basic investigations of its
ligand-binding and Ag presentation properties as well as in the
understanding of MR1-restricted T cell biology. Indeed, the
presence of MR1 on most APC lines and primary cells that also
express other classical and nonclassical HLA molecules can make
the unambiguous identification of microbe-specific MAIT cells
and their distinction from conventional T cells that express the
TRAV1-2 TCR chain problematic. Besides, solely relying on
known MAIT cell phenotypic markers could result in the exclu-
sion of previously undescribed bona fide MR1-restricted T cells.
So far, confirmation of MR1 restriction has exclusively relied on
the use of an anti-MR1 blocking mAb to abrogate activation (21),
yet this type of functional validation can sometimes produce in-
conclusive experimental data because of incomplete blockade. In
this context, the availability of isogenic model cell lines bearing
MR1 knockout mutations would be a valuable tool for reverse
genetics and loss of function studies.
The clustered regularly interspaced palindromic repeats
(CRISPR) and CRISPR-associated protein 9 (Cas9) genome
editing platform has recently been developed as a powerful tool to
induce targeted disruptive mutations in, or edit the DNA sequence
of, a specific gene (22–28). Current CRISPR/Cas9 genome editing
approaches rely on targeting the endonuclease activity of Strep-
tococcus pyogenes or Staphylococcus aureus (29) Cas9 to a 17- to
23-nt-long genomic DNA sequence using a single-guide RNA
(sgRNA) polynucleotide that acts both as a scaffold for Cas9 and
as a DNA tethering agent. Cas9 induces DNA strand breaks near a
so-called proto-spacer–associated motif (PAM) that are repaired
either via nonhomologous end joining, often introducing inser-
tions or deletions that disrupt the translational reading frame, or
via homologous recombination using a repair template (25).
CRISPR/Cas9 has been used to rapidly generate transgenic ani-
mals, correct deleterious mutations causing congenital diseases in
cell lines and pluripotent stem cells, or identify and validate
therapeutic targets. In this study, we report the generation of a
novel versatile all-in-one CRISPR/Cas9 lentiviral vector and its
use to derive isogenic clonal variants of carcinomic human alve-
olar basal epithelial A549 cells and of leukemic monocytic THP-1
cells commonly used to study the immune response to several
intracellular bacteria, including M. tuberculosis and Mycobacte-
rium smegmatis (2).
Materials and Methods
Generation of an all-in-one CRISPR/Cas9 lentivector
A synthetic polynucleotide sequence containing the canonical U6 RNA
polymerase III promoter and an sgRNA sequence containing the trans-
activating CRISPR RNA and the MR1-specific target sequence, based on
the design of Mali et al. (24), was purchased from Eurofins MWG Operon
(Ebersberg, Germany) and introduced in pCDNA.3-TOPO_wt-Cas9
(Addgene no. 41815) by nondirectional cloning at the unique Spe1 re-
striction site immediately upstream of the CMV promoter. To generate the
all-in-one lentivector construct, the plasmid region containing the U6
promoter–sgRNA as well as the CMV promoter and Cas9 sequences was
PCR amplified with primers containing Age1 and NsiI (pCDNA.3_Fwd
and pCDNA.3_Rev) restriction sites from the pCDNA.3-TOPO_U6-
sgRNA_wt-Cas9. This fragment was fused to a PCR amplicon consist-
ing of the second generation pRRL.sin.cppt.pgk-gfp.wpre lentivector
backbone developed by Didier Trono’s laboratory (Addgene no. 12252)
devoid of the human PGK promoter and GFP cDNA. This amplicon was
obtained by PCR amplification with primers containing matching restric-
tion sites (pRRL.0_Fwd and pRRL.0_Rev). The final sequence of the
resulting pRRL.sin.CRISPR/Cas9 plasmid and all the primer sequences are
provided in Supplemental Fig. 1 and Supplemental Table I, respectively.
Introduction of novel sgRNA target sequences
Repurposing of the CRISPR/Cas9 system was performed by introducing
new 19-nt target sequences using a PCR cloning approach whereby the new
sequence is fused to 59-phosphate–modified primers complementary to
plasmid sequences immediately flanking the target sequence (forward
primer. 59-GTTTTAGAGCTAGAAATAGCAAGTTAAx9-39, reverse primer,
59-GGTGTTTCGTCCTTTCCx10-39, where x represents nucleotides of the
target sequence). PCR amplification conditions were as follows: an initial
2-min denaturation step at 95˚C followed by 30 three-step cycles (30 s
denaturation at 95˚C, 30 s annealing at 53˚C, 5 min elongation at 72˚C)
and a final elongation step of 5 min at 72˚C using the Phusion high-fidelity
DNA polymerase (Thermo Scientific, Cambridge, U.K.). The PCR product
corresponding to the full-size plasmid (∼11 kbp) was gel extracted, puri-
fied, and circularized by ligation with standard T4 DNA ligase (Promega,
Southampton, U.K.). Ligation products were then transformed into
Escherichia coli XL10 Gold (Stratagene, La Jolla, CA). Bacteria were
plated onto Luria–Bertani agar containing 100 mg/ml carbenicillin (Bio-
chemical Direct) following a 1-h recovery step at 37˚C in SOC medium
(Invitrogen, Paisley, U.K.). After an overnight incubation at 37˚C, 10
colonies per new target sequence were tested by colony PCR to assess
plasmid integrity and confirm the presence of the sgRNA region of interest
(forward primer pLKO1.A; reverse primer gRNAcolPCR.R). PCR prod-
ucts of the expected size (450 bp) were purified, cleaned on DNA Clean
and Concentrator columns (Zymo Research, Irvine, CA), and sent for
sequencing. A total of five sgRNA target sequences were introduced for
testing: one targeting exon 1, three targeting exon 2, and one specific for a
site on exon 3 (Table I).
Cell culture and clonal expansion of MR12/2 cells
Adenocarcinoma HeLa (ATCC CCL-2), human acute monocytic leukemia
THP-1 (ATCC TIB-202), lymphoblastic chronic myelogenous leukemic
K-562 (ATCC CCL-243), and carcinomic alveolar basal epithelial A549
(ATCCCCL-185) cell lines were maintained in RPMI 1640 growth medium
(Life Technologies, Paisley, U.K.) supplemented with 2 mM glutamine, 50
U/ml penicillin, and 50 mg/ml streptomycin (Life Technologies) and 10%
FBS (Life Technologies), referred to as R10 hereon. Cells were passaged
when reaching 80% confluence using enzyme-free cell-dissociation buffer
HBSS (Life Technologies). Bulk A549 cells transfected with the CRISPR/
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Cas9 plasmid were sorted by flow cytometry by gating on the MR12
population. MR12/2 cells were isolated from bulk THP-1 cells transduced
with the CRISPR/Cas9 lentivector and subjected to MAIT cell positive
selection. The selection was performed by using THP-1 cells infected with
M. smegmatis at a 20:1 multiplicity of infection. Target cells were
cocultured for 7 d with the MAIT cell clone D481A9 at an E:T ratio of 1:2.
After the selection period, cells were transferred to flasks for a larger cell
culture and further expanded. Subsequently, the resulting cells were
clonally expanded by isolating single cells using a limiting dilution ap-
proach. An average of 0.3 cell was plated in individual wells of four flat-
bottom 96-well plates containing 200 ml medium. A total of 16 clonal
A549 and 20 THP-1 populations were then screened by flow cytometry.
Three A549 and five THP-1 clones were ultimately selected and analyzed
using a mismatch-specific endonuclease assay as described in Results.
T cell clones were cultured in RPMI 1640 media supplemented with 2 mM
glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin (Life Tech-
nologies), 10% FBS, 0.01 M HEPES buffer, nonessential amino acids,
sodium pyruvate (Life Technologies), 25 ng/ml IL-15 (PeproTech, Rocky
Hill, NJ), and either 20 or 200 IU/ml IL-2 (aldesleukin [Proleukin]; Pro-
metheus, San Diego, CA), depending on the stage of culture.
MAIT and T cell clones activation
IFN-g ELISPOT assays with the HLA-E–restricted T cell clone D160 1–23
were performed as described in Lewinsohn et al. (30). Briefly, A549 cells
or MR12/2 A549 cells (104/well) were incubated with 5 mg/ml M. tu-
berculosis pronase-digested cell wall (31) in RPMI 1640 medium sup-
plemented with 10% human serum for 2 h. D160 1–23 (104/well) was then
added to each well. The plate was incubated overnight at 37˚C and then
developed using an AEC Vectastain kit (Vector Laboratories). PHA stim-
ulation was used as a positive control for T cell signaling viability. Data
shown are representative of three independent experiments. The D426B1
and D481 MAIT cell clones were washed with RPMI 1640 medium and
then rested in RPMI 1640 supplemented with 50 U/ml penicillin and 50
mg/ml streptomycin, 2 mM L-glutamine, and 5% FBS overnight. A549
cells (wild-type [WT] and MR1 knockouts) were cultured in antibiotic-free
R10 overnight. A549 and THP-1 cells were exposed to M. smegmatis at a
multiplicity of infection of 100:1 (bacteria to cells) for 2 h in antibiotic-
free R10, followed by 2 h incubation with R10 containing 50 U/ml peni-
cillin and 50 mg/ml streptomycin (Life Technologies). A549 and THP-1
cells were washed to remove extracellular M. smegmatis. Control cells
were mock treated as if they had been coincubated with bacteria. A549 and
THP-1 cells were then plated into 96U-well plates at a density of 6 3 104
cells per well. MAIT cells (3 3 104) were then added to each well and
cultured overnight. Supernatant (60 ml) was then harvested, diluted to 120
ml with R5, and assayed for MIP-1b, TNF-a, and IFN-g ELISA (R&D
Systems) according to the manufacturer’s instructions. Data were plotted
and analyzed with GraphPad Prism software version 5.03. Activation of
the CD8+ T cell clone B9 specific for an octameric peptide (SELEIKRY)
derived from the EBV BZLF1 protein and presented by HLA-B*1801 (32)
was done by coculturing T cells with A549 WTor MR12/2 cells overnight
in 200 ml R5. A549 cells (1 3 106) were pulsed with each peptide con-
centration in 100 ml R5 for 2 h at 37˚C. The cells were washed with 10 ml
R5 five times, aspirating all excess supernatant between washes. The A549
cells were counted and resuspended at 6 3 105 cells/ml in a final volume
of 700 ml. Then, 100 ml cell suspension (i.e., 60,000 cells) was plated into
96-well plates. T cells (3 3 104) in 100 ml R5 were added into each well.
Then, the remaining APCs were centrifuged and the supernatant was
plated with T cells as a control to ensure that the T cell response was
mediated through APC presentation and not T:T presentation. Each assay
condition was performed in triplicate. For ELISAs, 50 ml supernatant per
well was used for TNF-a and IFN-g ELISA and 25 ml supernatant diluted
with 25 ml of R5 per well was used for MIP-1b. Supernatants were frozen
and assayed for MIP-1b and IFN-g in a sandwich ELISA assay (R&D
Systems) according to the manufacturer’s instructions.
Flow cytometry
The PE-conjugated anti-MR1 Ab clone 26.5 (BioLegend, London, U.K.)
was used to stain HeLa-MR1, A549, and THP-1 cells at the dilution rec-
ommended by the manufacturer. To stabilize the cell-surface levels of MR1,
A549 cells were incubated overnight in the presence of 50 mg/ml acetyl-6-
formylpterine (Schircks Laboratories, Jona, Switzerland) prior to staining
(11). Where indicated, the W6/32 monoclonal anti–HLA-ABC Ab con-
jugated to APC (eBioscience, Hatfield, U.K.) was also used to monitor
classical HLA-I levels on the cell surface. 7-Aminoactinomycin D (BD
Biosciences, Oxford, U.K.) or the viability Vivid Dye (Molecular Probes,
Life Technologies) was added to all the staining before data acquisition on
a FACSCalibur instrument (Becton-Dickinson, UK) or a FACSCanto II
(Becton Dickinson, Oxford, U.K.). Data analysis was performed with
FlowJo software (Tree Star, Ashland, OR) by drawing a population gate
on the forward scatter area/side scatter area plot and on viable cells
(7-aminoactinomycin D2 or Vivid2).
Monitoring of mutations at the MR1 locus
Genomic DNA from A549 and THP-1 cells was isolated with the GenElute
mammalian genomic DNA miniprep kit (Sigma-Aldrich, Gillingham, U.
K.). Mutations at the target site were detected using the CEL-I enzyme, as
part of the Surveyor assay (Transgenomic, Glasgow, U.K.), which cleaves
DNA duplexes bearing base pair mismatches, caused by insertions or
deletions at proximity of the PAM sequence, within the PCR amplicons
generated with primers flanking the genomic target site. The PCR forward
primer (SURV1_Fwd) is located in the intron region upstream of the target
site, and the reverse primer (SURV1_Rev) is located downstream on exon 2.
The predicted size of the full-length PCR product was 852 bp, and the
expected position of Cas9 cleavage (immediately downstream of the PAM
sequence) is located 521 bp downstream of the start of the forward primer
and 331 bp from the reverse primer. In the case of HeLa-MR1 cells, which
overexpress MR1 cDNA, a PCR amplicon flanking the sgRNA target se-
quences was obtained by amplifying a 360-bp region from template DNA
isolated as described above using a forward primer complementary to a
plasmid region immediately upstream of the MR1 cDNA (SURV2_Fwd)
and a reverse primer downstream of the target site (SURV2_Rev). To se-
quence the modified MR1 locus in the A549 clonal derivatives clone 9 and
clone 11, the same primers fused to the type IIs endonuclease BsaI were
used to amplify the genomic DNA and clone the amplicons into a cloning
vector (Addgene no. 32189). Plasmid minipreps from 10 colonies obtained
from the resulting transformation for each clone were sent for Sanger
sequencing at Eurofins MWG Operon.
Identification of CRISPR/Cas9 mutagenesis off-target effects
using genomics
Undertaking a BLAST search against the human genome refseq database
using the guide RNA (gRNA) sequence, we identified six sites (excluding
MR1) located within genes that contained sequence that differed at four or
fewer sites compared with the gRNA. Having identified these genes, we
undertook whole-genome sequence of two samples, clone 9 and clone 11, to
assess whether these genes contained off-target effects. To sequence the
sample, we extracted the genomic DNA from the two A549 clones using the
GenElute mammalian genomic DNA miniprep kit (Sigma-Aldrich). We
fragmented 1 mg DNA to an average of 300 bp fragments by sonication
and prepared libraries using NEBNext ultra library preparation kits (New
England Biolabs, Herts, U.K.). The libraries were sequenced using a
NextSeq 500, running high output 150-bp paired end sequencing to a depth
of .203 coverage for each genome. Taking the sequence reads generated,
we mapped these against the gene sequences of the target sites, and in five
of the six cases using the Burrows–Wheeler alignment tool (33), visual-
izing the mapping results using Artemis (34). To identify inserts that are
larger than those that could be detected by mapping, we screened all of the
Table I. CRISPR/Cas9 sgRNA target sequences within the MR1 gene tested in this study
gRNA Target Sequence (59→39) PAM (59→39) Exon Strand
A GGATGGGATCCGAAACGCCC AGG 2 +
B GGTGAAGCACAGCGATTCC CGG 1 2
C GTCCCTGAATTTATTTCGGT TGG 2 2
D GAACCTCGCGCCTGATCACT GGG 2 2
E GCAGTATGCATATGACGGGC AGG 3 2
Target sequences were identified by searching for GN19GG DNA motifs on either strand of the MR1 cDNA sequence. We selected five nonoverlapping target sequences
located in the first half of the MR1 coding sequence.
The Journal of Immunology 973










FIGURE 1. Description of the lentiviral CRISPR/Cas9 system and identification of gRNA target sequences efficiently disrupting MR1 gene expression.
(A) Graphic representation of the all-in-one lentiviral system generated for this study. The CRISPR/Cas9 elements derived from the pCDNA.3-TOPO_wt-
Cas9 plasmid were incorporated within the second generation pRRLSIN.cPPT.WPRE lentivector backbone between the Age1 and Nsi1 unique restriction
sites. (B) Positioning of three active sgRNA target sequences with respect to the intron/exon structure of the MR1 gene. (C) Disruption of MR1 protein
surface expression on HeLa reporter cells overexpressing MR1 transduced with lentiviruses expressing Cas9 in concert with a control gRNA (light blue
histogram), MR1 gRNAs A (dark green histogram), B (light green histogram), or D (orange histogram). Isotype control staining is shown as a solid light
gray histogram. The histogram plot shown is representative of four independent staining experiments. (D) Monitoring of mutations within the genomic
DNA of transduced HeLa cells. MR1 cDNA PCR amplicons generated with the genomic DNA of WT cells or of cells transduced with lentiviruses
expressing each sgRNA target were denatured, annealed, and digested with the CEL-I enzyme as described in Materials and Methods. Four hundred (WT
lane) or 200 ng of PCR products from unmodified HeLa-MR1 cells mixed with 200 ng amplicon generated with DNA obtained from cells transduced with
each sgRNA target (gRNA D, B, and A lanes) were used. Digestion of PCR amplicons was only obvious for the WT/gRNA A (Figure legend continues)
974 NEW TOOLS AND REAGENTS TO STUDY MAIT CELL BIOLOGY










reads generated using the sequence 20 bp on the 59 side of each of the off-
target sites identified above. Extracting these reads, we identified any cases
where larger deletions were present within these reads by manually ex-
amining the sequence of the reads by eye against the expected reference
sequence. Following this we also undertook an analysis to identify other
potential off-target sites that may not have been in genes, or detected by
our screen of the human genome. To do this, we identified all of the se-
quence reads that contained a sequence matching, or complementary to,
the gRNA at 15 of 20 bases, and extracted these into a set of fastq files. We
then assembled these sequences using Velvet and extracted all contigs with
a sequence length of .200 bp. In total, this analysis identified 7574 lo-
cations in sample clone 9 and 7516 locations in clone 11 for further in-
vestigation. Extracting the BLAST alignments for each of the sequences
queried, we examined, by eye, all of the alignments containing insertions
within the contig for evidence of insertions within 100 bp of the match to
the gRNA. In total, other than the known deletion within MR1 and the
detected RP11-46A10.6 site, we found no other cases where there
appeared to have been an off-target effect in either of our samples.
Sequencing data were submitted to the EMBL-EBI European Nucleo-
tide Archive (http://www.ebi.ac.uk/ena). The study accession number is
PRJEB12991. Sample accession and secondary accession numbers for
A549 clone 9 are ERS1078785 and SAMEA3891651. Sample accession
and secondary accession numbers for A549 clone 11 are ERS1078786 and
SAMEA3891652. Experiment accession and run accession numbers for
A549 clone 9 are ERX1378672 and ERR1307049. Experiment accession
and run accession numbers for A549 clone 11 are ERX1378673 and
ERR1307050.
Production of lentiviral particles and cell transduction
The pRRL.sin.CRISPR/Cas9 lentivector was cotransfected with the second
generation VSV.G envelope pMD2.G (Addgene no. 12259) and packaging
pCMV-dR8.74 (Addgene no. 22036) plasmids in HEK-293T cells by CaCl2
transfection in six-well plates. Lentiviral supernatants (∼10 ml total vol-
ume) were collected at 24 and 48 h, filtered using a 0.45-mm cellulose
acetate syringe filter, concentrated by centrifugation at 28,000 rpm for 2 h,
and resuspended in 0.5 ml R10. HeLa-MR1, THP-1, K562, or A549 cells
grown to ∼50% confluence in six-well plates were transduced with the
concentrated viral supernatant diluted 3-fold in a final volume of 3 ml.
Results
Development of a versatile all-in-one lentiviral CRISPR/Cas9
system
We chose to adapt the two plasmid delivery platform described
by Mali et al. (24), whereby the Cas9 and sgRNA elements are
expressed on separate plasmids, to generate a single delivery system
embedded within a second generation lentivector backbone. We
reasoned that such a tool would combine the ease of an all-in-one
delivery method with the high infectivity and broad cellular tropism
of lentiviruses. For this purpose, we introduced a codon-optimized
version of S. pyogenes Cas9 under the control of the CMV promoter
as well as a U6 RNA polymerase III promoter sgRNA complex
within the self-inactivating second generation lentivirus pRRL.sin.
cppt.pgk-gfp.wpre (Fig. 1A), a well-characterized lentiviral system
that produces high-titer viral particles. We designed the sgRNA so
that the 19-nt target sequence could be easily swapped through a
cloning PCR approach, a feature that distinguishes our lentivector
from other available CRISPR/Cas9 systems.
Generation of cell populations bearing CRISPR/Cas9-induced
mutations in the MR1 locus
A total of five lentivectors, each containing a different CRISPR target
sequence specific for the MR1 gene (Fig. 1B, Table I), were generated
and tested in a reporter system consisting of HeLa cells overexpressing
native human MR1 cDNA. MR1low/2 cells could be identified by flow
cytometry within HeLa-MR1 cell populations transduced with three of
the five lentiviruses (Fig. 1C). gRNA.A showed the highest disruption
efficiency both at the protein and DNA levels (Fig. 1C, 1D). Based on
these results, we selected gRNA.A to edit the genome of the A549 cell
line. We compared MR1 gene modifications induced in A549 cells in
which Cas9 and the MR1 gRNA.A were either stably or transiently
expressed using lentiviral transduction or plasmid DNA transfection,
respectively. Flow cytometry analysis showed that for both transient
and stable CRISPR/Cas9 expression, the overall mean fluorescence
intensities (MFIs) with anti-MR1 Ab were decreased and the pro-
portion of cells appearing MR1 low or negative was increased com-
pared with the control WT A549s (Fig. 1E). At the DNA level, the
Surveyor assay revealed that DNA mismatches were introduced at the
expected positions, as digestion of heteroduplex PCR amplicons
containing the CRISPR/Cas9 target sites from WT and modified cells
yielded two digestion products of the expected sizes (Fig. 1F). We also
used our CRISPR/Cas9 system to disrupt the endogenous MR1 genes
of the THP-1 and K562 cell lines. Transient transfection of K562 and
THP-1 cells with CRISPR/Cas9 plasmid DNA did not allow MR1
gene editing with high enough frequencies for monitoring with the
Surveyor assay. However, CRISPR/Cas9 lentivirus transduction suc-
cessfully generated MR1 indels in both cell lines (Fig. 1G, 1H). In the
case of THP-1, we used an enrichment strategy based on the positive
selection of MR1 mutants able to escape killing by a MAIT cell clone.
Following 7 d of coculture with MAIT cells at an E:T ratio of 1:2, we
observed an increase in the frequency of mutations in the MR1 gene
within the expanding THP-1 population, suggesting that the process
allowed for the selection of disruptive MR1 mutations (Fig. 1H).
Generation of MR12/2 A549 clones: phenotypic and genotypic
characterization
Although CRISPR/Cas9 gene disruption by lentiviral transduction
appeared more efficient than transient expression, we reasoned that
continuous expression of the gene-editing elements from a stable,
integrated vector within the cells was more likely to generate
detrimental off-target DNA cleavage, and we therefore elected to
heteroduplexes (lane gRNAA). Data shown are representative of two independent experiments. (E) A549 cells were lipofected with plasmid DNA containing
the CRISPR/Cas9 elements (including the gRNA A target sequence) or transduced with lentiviral particles made from the same plasmid. Eight days after
transduction/lipofection, cells were treated overnight with acetyl-6-formylpterine (50 mg/ml) prior to flow cytometry analysis. A549 cells stained with an
isotype control Ab are shown as a black histogram (MFI = 2.78), mock lipofected cells as a solid gray histogram (MFI = 9.53), cells transduced with
lentivirus as a red histogram (MFI = 5.84), and those lipofected with the CRISPR/Cas9 plasmid DNA as a blue histogram (MFI = 7.07). The data shown are
representative of three stainings. (F) Surveyor assay performed with a total of 500 ng PCR amplicon obtained from genomic DNA of unmodified A549 cells
or from cells lipofected or transduced with gRNA.A CRISPR/Cas9. Homoduplex WT DNA (lane 1) or heteroduplexes of annealed WT and modified
amplicons from transduced cells (lane 2) or lipofected cells (lane 3) were digested with the CEL-I DNA-mismatch–specific enzyme. Two bands matching
the sizes of the expected digestion products (521 and 331 bp) can be identified (indicated with red arrows). Undigested (lane 4) and digested (lane 5) assay
controls are shown. The gel shown is representative of at least five different experiments. (G) Surveyor assay performed with a total of 500 ng PCR
amplicon obtained from genomic DNA of unmodified K562 cells or from cells transduced with gRNA.A CRISPR/Cas9. Homoduplex WT DNA (lane 1) or
heteroduplexes of annealed WT and modified amplicons from transduced cells (lane 2) were digested with the CEL-I DNA-mismatch–specific enzyme.
Two bands matching the sizes of the expected digestion products (521 and 331 bp) can be identified (indicated with red arrows). (H) Surveyor assay
performed with a total of 500 ng PCR amplicon obtained from genomic DNA of unmodified THP-1 cells or from cells transduced with gRNA.A CRISPR/
Cas9. Homoduplex WT DNA (lane 1) or heteroduplexes of annealed WT and modified amplicons from transduced cells before and after MAIT cell
selection (lanes 2 and 3) were digested with the CEL-I DNA-mismatch–specific enzyme. Two bands matching the sizes of the expected digestion products
(521 and 331 bp) can be identified (indicated with red arrows). The data shown in Fig. 1G and 1H are representative of two independent experiments.
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use bulk-transfected A549 cells to derive MR12/2 clonal pop-
ulations by limiting dilution. Following a first screen by flow
cytometry of 16 clonal A549 derivatives (not shown), we se-
lected 8 candidates showing homogeneous cell surface MR1
protein expression. The putative clones 1, 9, and 11 consistently
displayed the lowest MFIs (Fig. 2A) and were taken forward for
further molecular analysis of their genomic DNA. Interestingly,
PCR amplification of the region flanking the sgRNA.A target
sequence yielded two products in the case of clone 9 (Fig. 2B).
In addition to a PCR amplicon of the predicted size (852 bp)
common to all samples, a smaller fragment, shorter by 100–150
bp, was amplified, likely indicating a deletion near the site of
Cas9 cleavage. Digestion of DNA heteroduplexes with the CEL-
I enzyme generated additional bands matching digestion prod-
uct sizes predicted by the positioning of the gRNA.A target and
PAM sequences within the amplicon (∼520 and 330 bp) for
clones 9 and 11 but not clone 1 (Fig. 2B). In the case of clone 9,
further characterization of PCR products by Sanger sequencing
revealed a 126-nt deletion spanning the intron/exon junction and
resulting in the partial deletion of the CRISPR/Cas9 target se-
quence on one allele (Fig. 2C). The other allele bore a single
nucleotide deletion as well as two base substitutions compared
with the MR1 reference sequence (Fig. 2C), in line with the
PCR analysis. Although it is unclear what the exact consequence
FIGURE 2. Characterization of A549 clonal derivatives bearing biallelic disruptive mutations in the MR1 gene. (A) Flow cytometry analysis of MR1
expression in eight different A549 clones obtained by limiting dilution and comparison with the bulk-transfected A549 parental cell line. Cells were treated
overnight with acetyl-6-formylpterin (50 mg/ml) prior to staining with a PE-conjugated anti-MR1 Ab and data acquisition. The histogram plot shown is
representative of three experiments. (B) Molecular characterization of mutations at the MR1 locus target site. PCR amplicons of WTA549 cells (lane 1) and
A549 clones 11 (lane 2), 9 (lane 3), and 1 (lane 4) are shown in the absence of hybridization and CEL-I digestion. The Surveyor assay was performed with a
total of 500 ng PCR amplicon obtained from genomic DNA of unmodified A549 cells or from the three different clones. Homoduplex WT DNA (lane 5) or
heteroduplexes of annealed WT and modified amplicons from clone 11 (lane 6), clone 9 (lane 7), or clone 1 (lane 8) were digested with the CEL-I DNA-
mismatch–specific enzyme. The gel shown is representative of at least four independent experiments. (C) Analysis of the MR1 genomic sequences re-
covered from A549 clone 9. The reference WT sequence is shown on top and the sequences recovered from clone corresponding to each allele are shown
underneath. (D) WT MR1 reference sequence (top) and sequences corresponding to each allele of A549 clone 11 are shown. Nucleotide deletions are shown as
red hyphens, and substitutions are shown as purple characters. Nucleotides corresponding to the sequence of the exon 2 MR1 are shown as green characters, the
19-nt gRNA.A target sequence is shown in blue characters, and the PAM sequence is shown in orange. (E) Predicted primary structures of the mutant MR1
proteins as determined by translating PCR amplicon DNA sequences. MR1 amino acids 26–50 are shown as alignments. The WT MR1 protein sequence is
indicated as gray shadows and out-of-frame reads are shown as pink shadows. C9A2, clone 9 allele 2; C11A1, clone 11 allele 1; C11A2, clone 11 allele 2.
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the large deletion has on MR1 protein structure, the latter mutation
likely disrupts the protein reading frame from amino acid 34 on-
ward (Fig. 2E). In the case of clone 11, an identical single nucle-
otide deletion within the sgRNA target sequence could be detected
on each allele (Fig. 2D). The reading frame on both alleles of clone
11’s coding sequence therefore shows the same frame shift as allele
2 of clone 9, where the native MR1 protein sequence is disrupted
from amino acid 34 onward (Fig. 2E). Collectively, the lack of MR1
staining by flow cytometry and the presence of disruptive mutations
on each allele for both clones indicated that MR1 expression was
almost certainly abrogated as a result of CRISPR/Cas9 mutagene-
sis.
MR1 CRISPR/Cas9 mutagenesis resulted in an unintended
nucleotide deletion in the RP11-46A10.6 pseudogene
To establish whether there were off-target effects resulting from
the CRISPR/Cas9 modification, we undertook whole-genome se-
quencing for A549 clones 9 and 11. We identified likely off-target
sites that occurred within genes (defined as sites varying at up to
five bases compared with the MR1gRNA target sequence), totaling
six possible genes where off-target effects could have been ob-
served. Mapping the whole-genome sequence data back to the
reference sequences for these genes, and for MR1, we identified
only one case of unintended mutation. This was in a pseudogene
bearing a high degree of sequence homology (94%) with the
targeted MR1 region (Fig. 3A) and containing the exact same
gRNA target sequence (Fig. 3B). In both samples the same nu-
cleotide deletion at position 16 of the gRNA sequence was ob-
served at this locus as on both clone 11 MR1 loci and on one MR1
locus of clone 9 (Figs. 2C, 2D, 3C). Another coding gene (STX6)
sits within the RP11-46A10.6 region. However, the exons making
up the STX6 protein–coding sequence are a considerable distance
from the RP11-46A10.6 target sequence (Fig. 3A). We also ex-
amined our sequence reads to identify any other off-target effects
that had longer deletions. Other than the one identified in MR1 for
clone 9, we observed no evidence for other long deletions in the
reads generated as part of the whole-genome sequencing (not
shown).
FIGURE 3. Results of whole-genome sequencing to identify off-target effects. (A) Figure generated from the Artemis comparison tool comparing the
DNA sequence of MR1 to the RP11-46A10.6 pseudogene (located between exon 1 and 2 of STX6 gene). The red ribbons indicate large contiguous regions
of 90%+ homology between the two genes, with the yellow ribbon being the region that contains the sequence targeted by the gRNA. The exons of MR1,
STX6, and the RP11-46A10.6 pseudogene are annotated in this region and are shown in turquoise, dark gray, and white, respectively. (B) Unintended on-
target effects within RP11-46A10.6 in samples clone 9 and clone 11. Two potential effects appear to be evident: one single base deletion seen in both clone
9 and clone 11, and one longer deletion in clone 9 (third read down from the top). The gRNA sequence is highlighted in yellow, and SNPs relative to the
reference are shown in red characters. (C) On-target effects on MR1 in samples clone 9 and clone 11. The single base deletion observed in both clones,
which is identical to that in RP11-46A10.6 relative to the gRNA target sequence, is evident for the vast majority of reads. The gRNA sequence is
highlighted in yellow, and single nucleotide polymorphisms relative to the reference are shown in red characters.
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A549 mutant clones infected with bacteria selectively fail to
activate MAIT cell clones
Next we sought to confirm MR1 deficiency at the functional level.
WTA549 cells or clones 9 and 11 infected withM. smegmatiswere
cocultured with the MAIT cell clones D426B1 and D481A9
known to express canonical TRAV1-2_TRAJ33 MAIT TCR
a-chain rearrangement differing in their CDR3 sequences and two
distinct b-chains (TRBV6-4 for D426B1 and TRBV20-1 for
D481A9) (2, 12). In contrast to infected WT A549s, which trig-
gered efficient MIP-1b and IFN-g release, MR1-deficient clones 9
and 11 failed to activate either MAIT cell clone (Fig. 4). These
results show that both A549 clonal derivatives are unable to pre-
sent bacterial Ags in the context of cell-surface MR1. Such a
distinct phenotype implies that CRISPR/Cas9 mutagenesis in-
duced biallelic disruptive mutations, resulting in loss of MR1
protein function in both A549 clones.
MR1 mutations do not affect the expression of nonclassical or
classical HLA molecules
To further assess the genetic integrity of both mutant A549 clones,
we performed additional phenotypic and functional experiments.
These established that cell-surface expression levels of classical
HLA-I molecules were not affected in MR1-deficient cells
(Fig. 5A, 5B). Moreover, both MR12/2 A549 clones were able to
present HLA-B*1801–restricted peptides derived from the EBV
protein BZLF1 to a CD8+ T cell clone with efficiencies similar to
the WTA549 cells, as evidenced by equivalent cytokine release in
peptide titration experiments (Fig. 5C, 5D). Finally, when cocul-
tured with the HLA-E–restricted CD8+ T cell clone D160 1–23,
the A549 clones 9 and 11 presenting M. tuberculosis cell wall
fractions triggered similar IFN-g secretion levels compared with
the WT A549 cells (Fig. 5E, 5F). Collectively, these data suggest
that classical and nonclassical HLA-I Ag presentation is intact in
the MR1-deficient cells.
Generation and functional characterization of MR12/2 THP-1
clones
The monocytic THP-1 cell line is a broadly used and well-
characterized tool to study bacterial phagocytosis and Ag presen-
tation (35). The availability of MR12/2 THP-1 cells would likely be
of interest to study MAIT cell responses to a range of pathogens.
Following the selection of bulk-transduced THP-1 cells bearing
increased MR1 mutations that conferred resistance to MAIT cell
killing (Fig. 1H), we sought to derive clonal populations by single-
cell dilution and assessed their MR1 phenotype. MR1 protein ex-
pression, as measured by flow cytometry, was markedly reduced in
bulk THP-1 cells that underwent the positive selection process
compared with the initial transduced preselection population
(Fig. 6A), confirming the mismatch nuclease assay (Figs. 1H, 6C).
All 20 tested THP-1 derivatives isolated by single-cell dilution of
the selected population showed MR1 expression levels similar to
those of the negative control used in the assay (Fig. 6B). Moreover,
CEL-I digestion of five of these cell populations pointed to the
presence of mismatch mutations at high frequencies within MR1
(Fig. 6C). Taken together, these data suggested that many, if not
most, THP-1 derivatives bore biallelic disruptive MR1 mutations.
Next we tested the ability of THP-1 cells to activate MAIT cells
following M. smegmatis infection. Similar to the A549 clone 9 and
clone 11, all the tested THP-1 derivatives failed to activate both
D426B1 and D481A9 MAIT cell clones, as measured in cytokine
release assays (Fig. 7), whereas the infected parental THP-1 cells
induced the secretion of high levels of both TNF-a and IFN-g by
FIGURE 4. MAIT cells fail to recognize A549 derivatives clone 9 and clone 11 infected with M. smegmatis. The D481A9 and 426B1 MAIT cell clones
were cocultured with the indicated A549 APCs infected with M. smegmatis or not as described in Materials and Methods. Supernatants were collected
following overnight incubation. MIP-1b produced by MAIT cell clones D481A9 (A) and D426B1 (B), respectively, were quantified by ELISA. IFN-g levels
were also measured for both D481A9 (C) and D426B1 (D). Assays were carried out in triplicate wells. Means 6 SEM are shown on the graph using data
representative of three experiments.
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D481A9 (Fig. 7A, 7C) by D426B1 (Fig. 7B, 7D), thereby dem-
onstrating that these cells are unable to present MR1-restricted Ags
and confirming their knockout status.
Discussion
RNA-guided genome engineering with CRISPR/Cas9 is a versatile
and efficient tool to manipulate the genome of cell lines, including
somatic and germinal cells. We have adapted this technology in a
novel all-in-one lentiviral vector for the simultaneous delivery of
the Cas9 endonuclease and an associated sgRNA. We designed
sgRNA target sequences specific for the human MR1 locus and,
following an initial screen in a reporter system, selected a target
sequence we used to efficiently disrupt the expression of endog-
enous MR1 in three cell lines. We subsequently expanded clonal
A549 and THP-1 populations bearing disruptive biallelic MR1
mutations. T cell assays where MAIT cells were activated by the
parental A549 and THP-1 cell lines but failed to recognize cells
obtained by limiting dilution upon infection with M. smegmatis
confirmed MR1 protein loss of function. Importantly, CRISPR/
Cas9-directed mutagenesis in these cells did not alter Ag pro-
cessing and presentation by classical and nonclassical HLAs,
highlighting the specificity of the genome editing approach and
validating the use of these two clones to accurately characterize
MR1-restricted Ags and their recognition by MAIT cells.
The two MR1-deficient A549 clones characterized in this study
were generated from transient expression of an sgRNA and Cas9
elements in the parental cell line. The expression level of MR1 on
the surface of A549 cells is relatively weak, and monitoring by flow
cytometry, even after stabilization with high acetyl-6-formylpterine
concentrations, did not allow us to unambiguously identify a
population of MR12 cells in the bulk-transfected population
(Fig. 1E). However, the CEL-I mismatch-specific nuclease assay
clearly showed that mutations were introduced at the intended site
within the MR1 gene (Fig. 1F). The level of MR1 disruption was
increased following flow cytometry cell sorting of an MR12/low
population (not shown) from which we isolated and expanded
individual clones by limiting dilution. A screen of 16 clonal
populations identified eight derivatives that exhibited MR1 MFIs
consistently lower than those of the parental cells (Fig. 2A). Three
of these clones appeared MR12 by flow cytometry and were taken
forward for molecular analysis of genomic DNA. Disruptions at
the MR1 locus could be identified in two clones using the CEL-I
assay, and Sanger sequencing confirmed the presence of frame-
shift mutations on both alleles for each clone (Fig. 2C). Overall 2
of 16 of the clones (12.5%) displayed the genotype of interest.
This suggested that extending the induction of disruptive MR1
mutations in other cell lines and, possibly, in primary cells using
this system should be possible. We confirmed this by applying
FIGURE 5. MR1 disruption does not af-
fect HLA class Ia and HLA-E Ag presen-
tation. (A) Representative cell surface HLA-
I expression by A549 cells. MFI values were
56.4 (isotype control), 8733 (WT A549),
9880 (clone 11), and 8682 (clone 9). (B)
MFI from three surface HLA-I staining of
A549 WT and MR12/2 cells. Individual
MFI datum points as well as mean values 6
SEM are shown. The data shown are rep-
resentative of two independent staining ex-
periments. (C and D) Secretion of IFN-g and
MIP-1b cytokines by CD8+ T cell clones B9
in response to increasing concentrations of
an agonist peptide (SELEIKRY) derived
from the EBV BZLF1 protein and presented
by HLA-B*1801 expressed on the surface of
WT A549, clone 9, or clone 11 as indicated
in the key. (E) Activation of the D160 1–23
HLA-E–restricted CD8+ T cell clone in re-
sponse to increasing numbers of WT A549
or A549 MR12/2 clone 9 cells exposed to
pronase-digested M. tuberculosis cell wall
extracts. (F) Activation of the D160 1–23
HLA-E–restricted CD8+ T cell clone mea-
sured as spot-forming units in response to
increasing numbers of WT A549 or A549
MR12/2 clone 11 exposed to pronase-
digestedM. tuberculosis cell wall extracts in
ELISPOT assays. The data shown are rep-
resentative of two independent experiments.
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CRISPR/Cas9 mutagenesis to K562 and THP-1 cells. In both lines
we were able to show the induction of MR1 mutations at the
intended target site with the mismatch nuclease assay (Fig. 1G,
1H). In the case of the highly phagocytic THP-1 cell line, we set
up a mutation enrichment strategy relying on the positive selection
of THP-1 mutants unable to present MR1 Ags following infection
with M. smegmatis and on MAIT cell cytotoxicity as a selecting
force. The frequency of MR1 mutations was markedly increased
by this selection process (Figs. 1H, 6A, 6C), and we were able to
isolate monoclonal THP-1 cells by limiting dilution and expan-
sion. All these derivatives failed to stain with anti-MR1 Ab
(Fig. 6A, 6B), and the five we tested functionally did not activate
MAIT cells in cytokine release assays (Fig. 7). Although we did
not establish the clonal nature of these populations, it seems likely
that at least some of them are MR12/2 clones that can be used to
study intracellular bacteria of different species than those infecting
the A549 cells. The fact that all the THP-1 derivatives failed to
activate MAIT cells (Fig. 7) is a clear indication of the efficiency
of the positive selection approach we undertook, which could
prove a useful and powerful way to establish the MHC restriction
or Ag specificity of T cells without having to generate clonal
target cell derivatives bearing biallelic mutations. Single-cell
cloning is a cumbersome process and can be impossible to im-
plement in the context of primary cells with limited proliferative
capacity. Moreover, it is conceivable that the efficiency of this
approach can be accurately quantified through a deep amplicon
sequencing approach.
Concerning the nature of the A549 genomic mutations, it is
notable that, on one allele of clone 9, we identified a 126-bp de-
letion spanning the junction between MR1 exon 2 and the flanking
upstream intronic region and ending at the sgRNA target sequence
(Fig. 2C). Such large deletions are not commonly observed fol-
lowing nonhomologous end joining genome editing with nuclease
systems (CRISPR/Cas9 or others). The genomic DNA disruptions
observed on the three other alleles were more in line with what is
described in the literature, as we identified a single nucleotide
FIGURE 6. Isolation and characterization of THP-1 clonal derivatives bearing disruptive mutations in the MR1 gene. (A) Flow cytometry analysis of MR1
expression in THP-1 cells transduced with MR1 CRISPR/Cas9 lentiviral particles before and after enrichment of MR1-deficient cells by selection with the
426B1 MAIT cell clone, as indicated in the key to the figure. MFI values were: unstained, 45.5; isotype control, 53.9; WT THP-1, 1033; preselection edited
cells, 820; and postselection edited cells, 161. (B) Staining of 20 different THP-1 clones obtained by limiting dilution from the postselection THP-1 parental
cell line. MFI values of the indicated populations are represented. The data shown are representative of two independent experiments. (C) Molecular char-
acterization of mutations at the MR1 locus target site. CEL-I–digested PCR amplicon homoduplexes of WT THP-1 cells (lane 1), heteroduplexes of WT THP-1
cells DNA hybridized with DNA from bulk-transduced THP-1 preselection (lane 2) and postselection (lane 3), as well as clones 3 (lane 4), 6 (lane 5),
7 (lane 6), 11 (lane 7), and 13 (lane 8). The Surveyor assay was performed with a total of 500 ng PCR amplicon obtained from genomic DNA of unmodified
THP-1 cells or from the different bulk and clonal populations. The gel shown is representative of two independent experiments.
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deletion common to all three other alleles that disrupted the pro-
tein reading frame from amino acid 34 onward (Fig. 2C–E).
Although the MR1 target sequence we used bears little ho-
mology with other classical and nonclassical HLA genes, it was
important to test whether other Ag presentation pathways had been
disrupted as a result of the genome editing process. Albeit not
exhaustive, our control experiments showed that classical HLA
class I expression (Fig. 5A, 5B) as well as presentation of cognate
exogenous peptide to an HLA-B*1801–restricted CD8+ T cell
clone (Fig. 5C, 5D) by both A549 derivatives were equivalent to
the unmodified A549 cells. Moreover, both clones activated an
HLA-E–restricted CD8+ T cell clone with efficiencies similar to
WTA549 (Fig. 5E, 5F). Collectively, these results imply that both
the expression and processing of HLA alleles as well as peptide
presentation are intact in these cells. Additionally, the basic
properties of A549 clones 9 and 11 such as growth rate and
morphology appeared unaffected (not shown); however, this
does not exclude the possibility of other off-target mutations in
unrelated genes. To address this possibility, we performed whole-
genome sequencing on both A549 clones and searched for mu-
tations in genes containing sequences with homology to our MR1
gRNA target. In total we examined 7580 locations with off-target
potential across the genome. We found no mutations in these
except in the RP11-46A10.6 pseudogene (Fig. 3B) locus that
contains DNA regions of high homology with some MR1 introns
and exons (Fig. 3A). Most notably, the 23 nucleotides composing
the MR1 gRNA target sequence and adjacent PAM are 100%
conserved in RP11-46A10.6 (Fig. 3B, 3C). Interestingly, the
RP11-46A10.6 A549 loci contained the same mutation we iden-
tified as being the most common in MR1, that is, a single base
deletion at position 17 of the sgRNA seed region. Even though this
mutation was clearly unintended, it is on-target in the sense that it
occurred at a locus bearing the full intact sgRNA target and PAM
sequences. The potential for such an unintended effect was missed
during the initial assessment of our MR1 gRNA candidates be-
cause we only searched for gRNA target and PAM sequence ho-
mology against coding genomic regions using the BLAST tool.
Both A549 clones bear this pseudogene mutation, most likely in a
homozygous manner, yet we anticipate no functional conse-
quences given the noncoding nature of this locus. The fact that our
sgRNA induced mutation in both MR1 and the RP11-46A10.6
pseudogene, where there is a 100% conservation of sequence,
serves to highlight both the high efficiency and on-target speci-
ficity of CRISPR/Cas9.
The availability of MR1-deficient cells should be useful for
fundamental investigations into the biology of MR1 and MR1-
restricted T cells as well as for the potential development of
therapeutic and diagnostic tools seeking to harness this invariant
nonclassical HLA molecule. First, MR12/2 cells will help with the
unambiguous identification of MR1-restricted T cells because,
unlike Ab blockade, the absence of MR1 completely obliterates
MAIT cell responses to bacterially infected cells (Fig. 4). Second,
in in vitro activation experiments, MR1-deficient APCs should
allow characterizing and quantifying MR1-restricted T cells
within the bulk pathogen-specific T cell response. Third, it is
unclear at present whether bacterial Ags presented by MR1 show a
degree of chemical and structural variability (36) and whether
responding T cells can discriminate between distinct cognate
MR1/Ag complexes via their clonal TCR. MR12/2 cells should be
a useful tool to test the ability of individual putative MR1 ligands
to activate T cells. This would require obtaining chemically pure
compounds used to pulse MR1-sufficient or -deficient APCs to test
the response of T cell clones with distinct TCR usage and assess
MR1 restriction. Fourth, the availability of cell lines in which
endogenous MR1 expression is abrogated could also prove useful
to knock-in mutated or chimeric reporter MR1 proteins and
characterize the cellular biology of MR1, such as its trafficking
and distribution in subcellular compartments. Such an approach
may help shed light on the mechanisms governing the processing
and loading of vitamin B derivatives without interference from
endogenous MR1 molecules. Finally, MR12/2 cells are likely to
prove valuable for the generation and/or validation of biologicals
and compounds targeting MR1.
In summary, we have generated THP-1 and A549 isogenic cells
deficient for MR1 and a CRISPR/Cas9 lentivector that should allow
applying the same process to other cell types. These reagents
should facilitate investigations seeking to further understand the
mechanisms underpinning the unique biology of MR1 and to
harness its therapeutic and diagnostic potential. In the future,
similar genome editing approaches could also be extended to fa-
FIGURE 7. THP-1 single-cell de-
rivatives infected with M. smegmatis
are unable to activate MAIT cells.
The D481A9 and 426B1 MAIT cell
clones were cocultured with the in-
dicated THP-1 derivatives infected
with M. smegmatis or not as de-
scribed in Materials and Methods.
Supernatants were collected follow-
ing overnight incubation. TNF-a pro-
duced by MAIT cell clones D481A9
(A) and D426B1 (B), respectively, was
quantified by ELISA. IFN-g levels
were also measured for both D481 (C)
and D426B1 (D). Assays were carried
out in triplicate wells. Means 6 SEM
are shown on the graph using data
representative of two experiments.
Assays were carried out in tripli-
cate wells.
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cilitate basic and applied research on other invariant MHC-related
proteins such as the CD1 family, HLA-E, or other MHC class Ib
gene products that may serve as ligands for the TCR (37).
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